Learnings from Implementation Strategies to Improve Lipid Management.

Purpose Of Review: Lowering low-density lipoprotein (LDL)-cholesterol reduces cardiovascular risk. International lipid management guidelines recommend LDL-cholesterol goals or thresholds for initiating lipid-lowering therapy. However, contemporary real-world studies have shown that many high- and very high-risk patients are not attaining LDL-cholesterol goals and are not receiving intensive lipid-lowering therapies.

Continuous Flow Synthesis of Copper Oxide Nanoparticles Enabling Rapid Screening of Synthesis-Structure-Property Relationships.

An adjustable and scalable method for the continuous flow synthesis of cupric oxide nanoparticles (CuO NPs), targetted the reduction of their activity to synthetic biomembranes to inform the fabrication of nanoparticles (NPs) with reduced toxicity for commercial applications. By manipulating key factors; temperature, residence time, and the ratio of precursor to reductant, precise control over the morphology of CuO NPs is achieved with X-ray diffraction (XRD) and transmission electron microscopy (TEM) confirming the formation of needle-shaped CuO NPs. One-variable-at-a-time studies reveal a relationship between the synthesis conditions and the characteristics of the resultant NPs, with CuO NPs varying controllably between 10-50 nanometres in length and 4-10 nanometres in width.

Investigating proteogenomic divergence in patient-derived xenograft models of ovarian cancer.

Within ovarian cancer research, patient-derived xenograft (PDX) models recapitulate histologic features and genomic aberrations found in original tumors. However, conflicting data from published studies have demonstrated significant transcriptional differences between PDXs and original tumors, challenging the fidelity of these models. We employed a quantitative mass spectrometry-based proteomic approach coupled with generation of patient-specific databases using RNA-seq data to investigate the proteogenomic landscape of serially-passaged PDX models established from two patients with distinct subtypes of ovarian cancer.